“With our deep expertise in antiviral drug development, continually expanding knowledge of COVID-19 and support from BARDA, we will advance the pre-exposure prophylaxis program for S-892216 at ...
The "Human Immunodeficiency Virus (HIV): Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the risk factors, comorbidities, ...
allAfrica.com on MSN1d
Africa: U.S. Aid Funding Cuts Put HIV Prevention At Risk, Warns UNAIDSThe US pause in foreign assistance funding has created "confusion" in the vital work of community HIV prevention, despite a ...
The lawsuit claimed Gilead "exaggerated" its role in developing the drug's HIV-prevention regimen, known as PrEP, or pre-exposure prophylaxis, ignored the CDC's contributions and refused to ...
Gilead's HIV franchise remains a cornerstone of its business, with recent developments in its long-acting pre-exposure prophylaxis (PrEP) drug ... with $500 million of that increase coming ...
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
Some South African organizations that assist people with HIV are in limbo, after the United States put a 90-day freeze on most foreign aid. The U.S. State Department later added a waiver for ...
There were no roll calls in the House or Senate last week. When the 2024 legislative session ended on Jan. 1, thousands of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback